Stemtech Corp (STEK) stock: key figures, P/E, revenue and dividend

Industrials · United States · ISIN US85859W1027

Price
0.00 USD
Market cap
299,703.29 USD
P/E (2026)
–
P/S (2026)
–
Dividend yield
0.00 %
Net margin
–
Return on equity (ROE)
–
Return on assets (ROA)
–

Stemtech Corp financials

Fiscal year2025
Revenue2.88 m USD
Gross profit2.31 m USD
Operating income-2.71 m USD
EBIT-2.60 m USD
Net income-4.05 m USD
Diluted EPS – continuing operations-0.02 USD

Full history since 2009, charts and your own formulas

This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.

About Stemtech Corp

Stemtech Corporation, a stem cell nutrition company, develops science-based products to help the body maintain healthy stem cell physiology in the Americas, Latin America, and Asia. The company's products enhance and support the work of the body's stem cells by releasing more stem cells, helping to circulate them in the blood, and migrate them into tissues, where they can perform their daily function of renewal for optimal health. It offers its products under the RCM System, stemrelease3, and Stemflo MigraStem brands; oral health care under the OraStem brand; and rapid renew stem cell peptide night cream under the Collect One brand name, as well as Cellect One shield hypochlorous acid skin care products. It sells products through independent distributors. Stemtech Corporation was founded in 2005 and is headquartered in Naples, Florida.

More stocks

All stocks →

Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.